Side-by-side · Research reference

FOXO4-DRIvsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

FOXO4-DRI

Vesugen

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

Vesugen

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Route

SQ (animal)

No human route established.

Subcutaneous or intramuscular

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Case series report treatment courses in elderly arterial insufficiency

Clinical status

No human trials completed

—

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Frequency

—

Not specified in available literature

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

FOXO4-DRI

Vesugen

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Vesugen

—

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

FOXO4-DRI

Vesugen

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

—

06Stack Synergy

FOXO4-DRI

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)